DIALysis With EXpanded Solute Removal (NCT06660277) | Clinical Trial Compass
RecruitingNot Applicable
DIALysis With EXpanded Solute Removal
Canada4,800 participantsStarted 2025-08-12
Plain-language summary
The goal of this clinical trial is to evaluate the health effects of expanded hemodialysis in patients receiving hemodialysis. The main question it aims to answer is:
1\) Does expanded hemodialysis reduce the risk of death from any cause?
Researchers will compare expanded hemodialysis to conventional hemodialysis (the treatment currently used for the majority of patients receiving hemodialysis) to see if expanded hemodialysis works to improve patient outcomes.
Participants will continue to receive their regularly scheduled hemodialysis treatments using either a super high-flux/expanded dialysis filter or a high-flux/conventional dialysis filter. All other aspects of treatments remain the same. No additional tests or visits are required. Data will be obtained using administrative healthcare databases and medical record review (at a subset of participating locations).
Who can participate
Age range45 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. One of:
✓. Age 60 years or older; or
✓. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and
✓. Receiving any form of dialysis regularly for the previous 90 days; and
✓. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and
✓. A valid provincial or territorial health insurance card number.
Exclusion criteria
✕. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of:
✕. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or
✕. Planned to receive HDF; or
✕. Planned to receive nocturnal HD; or
What they're measuring
1
Primary Outcome of All-Cause Mortality
Timeframe: From randomization to event (death) or end of treatment (average 2.9 years follow-up), whichever occurs first
Trial details
NCT IDNCT06660277
SponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
. Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or
✕. Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or
✕. An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or
✕. Another medical, psychosocial, or logistical reason; or